Genix Pharmaceuticals Corporation manufactures and converts dietary supplements and neutraceuticals for the natural health care products and supplement industries primarily in Canada and the United States.
The last earnings update was 10 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Genix Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Genix Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Genix Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Genix Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
Genix Pharmaceuticals has negative assets, we can't compare the value of its assets to the CA Personal Products industry average.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Genix Pharmaceuticals's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genix Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Personal Products industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Genix Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Genix Pharmaceuticals's earnings growth to the Canada market average as no estimate data is available.
Unable to compare Genix Pharmaceuticals's revenue growth to the Canada market average as no estimate data is available.
Unable to determine if Genix Pharmaceuticals is high growth as no earnings estimate data is available.
Unable to determine if Genix Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
All data from Genix Pharmaceuticals Company Filings, last reported 2 months ago, and in
Trailing twelve months (TTM)
annual period rather than quarterly.
TSXV:GENX Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions)
Net Income *
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
It is difficult to establish if Genix Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
It is difficult to establish if Genix Pharmaceuticals has efficiently used its assets last year compared to the North America Personal Products industry average (Return on Assets) as it is loss-making.
It is difficult to establish if Genix Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
Genix Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Genix Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Genix Pharmaceuticals's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
Genix Pharmaceuticals has no long term commitments.
This treemap shows a more detailed breakdown of
Genix Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
High level of physical assets or inventory.
Genix Pharmaceuticals has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Sina Salehi Pirooz has been Director of Alta Natural Herbs & Supplements Ltd. since August 3, 2018 and its Chief Executive Officer since March 11, 2019. Mr. Pirooz is the Owner of Coal Harbour Compounding Pharmacy and President of SP RX Services. Mr. Pirooz is a registered and practicing pharmacist and a professional member of the College of Pharmacists of British Columbia since 2003. Mr. Pirooz has over 18 years experience in the international pharmaceuticals industry and has been a professional member of the College of Pharmacists of British Columbia since 2003. Mr. Pirooz has provided consulting, pharmacist and pharmacy management services to many of Canada's leading pharmacies and drug stores including Rexall Drugs, Pharmasave and Guardian Pharmacies. He is also actively engaged in the sales, marketing and export of pharmaceuticals, OTC drugs and health supplements to the Middle East.
Insufficient data for Sina to compare compensation growth.
Insufficient data for Sina to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
CEO & Director
CFO & Director
Board of Directors Tenure
Average tenure of the
board of directors in years:
The average tenure for the Genix Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors
CEO & Director
CFO & Director
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Genix Pharmaceuticals individual insiders in the past 3 months, but not in substantial volumes.
What Kind Of Shareholder Owns Most Genix Pharmaceuticals Corporation (CVE:GENX) Stock?
Genix Pharmaceuticals is a smaller company with a market capitalization of CA$1.3m, so it may still be flying under the radar of many institutional investors. … Our analysis of the ownership of the company, below, shows that institutional investors have not yet purchased shares. … See our latest analysis for Genix Pharmaceuticals TSXV:GENX Ownership Summary, August 21st 2019 What Does The Lack Of Institutional Ownership Tell Us About Genix Pharmaceuticals?
What Kind Of Share Price Volatility Should You Expect For Genix Pharmaceuticals Corporation (CVE:GENX)?
If you're interested in Genix Pharmaceuticals Corporation (CVE:GENX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.
Genix Pharmaceuticals Corporation manufactures and converts dietary supplements and neutraceuticals for the natural health care products and supplement industries primarily in Canada and the United States. The company offers herbal, botanical, and marine-based neutraceuticals. It also acts as a contract manufacturer/converter of raw material powders with all conversion from powders to capsules to bottling and packaging. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is headquartered in Vancouver, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.